Table 3.

Overall survival

CohortAny cGVHDLim, extMild, mod, sevLow, int, high
RR3-15095% CIRR3-15095% CIRR3-15095% CIRR3-15095% CI
IBMTR-1 1.0 (0.8-1.2) 0.63-155 (0.4-0.8) 0.53-155 (0.4-0.7) 0.53-155 (0.3-0.7) 
   1.3 (1.1-1.7) 1.03-155 (0.7-1.4) 1.23-155 (0.9-1.5) 
     3.3 (2.5-4.4) 2.3 (1.7-3.2) 
IBMTR-2 1.43-151 (1.0-1.8) 0.83-155 (0.5-1.2) 0.7 (0.4-1.0) 0.83-155 (0.5-1.2) 
   2.0 (1.5-2.8) 1.13-155 (0.7-1.6) 2.0 (1.4-3.0) 
     5.9 (4.1-8.5) 2.7 (1.7-4.0) 
NMDP 1.43-152 (1.1-1.9) 1.0 (0.7-1.6) N/A  0.63-153 (0.4-1.0) 
   1.5 (1.2-2.0)   1.13-153 (0.8-1.6) 
       2.0 (1.3-3.0) 
CohortAny cGVHDLim, extMild, mod, sevLow, int, high
RR3-15095% CIRR3-15095% CIRR3-15095% CIRR3-15095% CI
IBMTR-1 1.0 (0.8-1.2) 0.63-155 (0.4-0.8) 0.53-155 (0.4-0.7) 0.53-155 (0.3-0.7) 
   1.3 (1.1-1.7) 1.03-155 (0.7-1.4) 1.23-155 (0.9-1.5) 
     3.3 (2.5-4.4) 2.3 (1.7-3.2) 
IBMTR-2 1.43-151 (1.0-1.8) 0.83-155 (0.5-1.2) 0.7 (0.4-1.0) 0.83-155 (0.5-1.2) 
   2.0 (1.5-2.8) 1.13-155 (0.7-1.6) 2.0 (1.4-3.0) 
     5.9 (4.1-8.5) 2.7 (1.7-4.0) 
NMDP 1.43-152 (1.1-1.9) 1.0 (0.7-1.6) N/A  0.63-153 (0.4-1.0) 
   1.5 (1.2-2.0)   1.13-153 (0.8-1.6) 
       2.0 (1.3-3.0) 

Lim, ext indicates limited or extensive involvement; mild, mod, sev indicates mild, moderate, or severe clinical involvement; low, int, high indicates low risk, intermediate risk, high risk; RR, relative risk; CI, confidence interval; and N/A, not applicable.

F3-150

Adjusted for disease type (acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia), disease stage (early, intermediate, advanced), age (years), patient-donor sex matching, and presence of prior acute GVHD (yes, no).

F3-151

P ≤ .01 compared with no cGVHD.

F3-152

P ≤ .001 compared with no cGVHD.

F3-153

P ≤ .01 compared with the next most severe category.

F3-155

P ≤ .0001 compared with the next most severe category.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal